Anti-Human DR5 (Drozitumab) – Fc Muted™
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Isotype : | Human IgG1lambda |
| Purification : | >=95% monomer by analytical SEC |
| Content : | Concentration : >= 5.0 mg/ml This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. |
| Storage condition : | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Alternative Name : | DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5 |
| Immunogen Information : | DR5 scFv |
Expression Host : HEK-293
Pathogen Testing : To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of this recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only.
Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.1 Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.
Endotoxin : <= 1.0 EU/mg as determined by the LAL method
The suggested concentration for Drozitumab biosimilar antibody for staining cells in flow cytometry is <= 0.25 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
